trial · primary record
casdatifan
Clear Cell Renal Cell Carcinoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 362 |
| Primary completion | 2029-03 |
| Primary endpoint | Number of participants with dose limiting toxicities (DLTs) |
| Registry ID | NCT05536141 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:23.083Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05536141
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- casdatifan · compound